Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922277 | 0.83 | KDR (0.52) | HDAC1HDAC2RAB9AHDAC3FADS1 | |
| SCHEMBL1585024 | 0.82 | NFKB1 (0.52) | KDM4ESORT1ALDH1A1HTTRAB9A | |
| SCHEMBL28049181 | 0.79 | KCNQ3 (0.50) | KDM4ESORT1ALDH1A1HTTRAB9A | |
| SCHEMBL28049179 | 0.77 | KCNQ3 (0.48) | KDM4ESORT1ALDH1A1HTTRAB9A | |
| SCHEMBL24684142 | 0.74 | NFKB1 (0.51) | KDM4ESORT1RAB9ASMN1; SMN2JUN | |
| SCHEMBL28789750 | 0.73 | P2RX1 (0.60) | GAASMN1; SMN2TMPRSS4 | |
| SCHEMBL29732883 | 0.73 | P2RX1 (0.60) | GAASMN1; SMN2TMPRSS4 | |
| SCHEMBL4969026 | 0.72 | PTGS1 (0.54) | GAASORT1RAB9ASMN1; SMN2TRPV1 | |
| SCHEMBL1585348 | 0.72 | PDPK1 (0.51) | PDPK1 | |
| SCHEMBL1585349 | 0.72 | NPC1 (0.50) | HDAC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3466929-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3070077-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| EP-3070077-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-3070077-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| CN-102665718-A | Heterocyclic compounds useful as pdk1 inhibitors | BIOGEN IDEC INC | 2012-09-12 | — | — | CN | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| EP-2485731-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GAA 1458/4885KDM4E 1364/4885POLB 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.